The advisory committee will weigh in on molnupiravir’s safety concerns, which have been raised by some experts, before the FDA makes a decision on authorization of the drug, the report https:// said.
Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.
Merck is developing molnupiravir in partnership with U.S.-based Ridgeback Biotherapeutics.
In early October, data showed Merck’s drug could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, pummelling shares of coronavirus vaccine makers.
The FDA and Merck did not immediately respond to Reuters’ requests for comment.